MicroRNA-32 and MicroRNA-548a Promote the Drug Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting ROBO1 and Inhibiting the Activation of Wnt/β-Catenin Axis

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature2518329364287
   PubMed Web of Science ®Google Scholar
• Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017;9(11):913–927. doi:10.2217/imt-2017-005229338609
   PubMed Web of Science ®Google Scholar
• Wei Y, Wu S, Xu W, et al. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP. Thorac Cancer. 2017;8(1):26–32. doi:10.1111/1759-7714.1240027813328
   PubMed Web of Science ®Google Scholar
• Wang L, Ma L, Xu F, et al. Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 2018;9(7):761–768. doi:10.1111/1759-7714.1265229726094
   PubMed Web of Science ®Google Scholar
• Griguer CE, Oliva CR. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria. Curr Pharm Des. 2011;17(23):2421–2427. doi:10.2174/13816121179724925121827418
   PubMed Web of Science ®Google Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309. doi:10.1038/s41586-019-1730-131723286
   PubMed Web of Science ®Google Scholar
• Shioya M, Obayashi S, Tabunoki H, et al. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol. 2010;36(4):320–330. doi:10.1111/j.1365-2990.2010.01076.x20202123
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.02816989803
   PubMed Web of Science ®Google Scholar
• Wei L, Wang X, Lv L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019;18(1):147. doi:10.1186/s12943-019-1086-z31651347
   PubMed Web of Science ®Google Scholar
• Drayton RM. The role of microRNA in the response to cisplatin treatment. Biochem Soc Trans. 2012;40(4):821–825. doi:10.1042/BST2012005522817741
   PubMed Web of Science ®Google Scholar
• Ma Y, Yuwen D, Chen J, et al. Exosomal transfer of cisplatin-induced miR-425-3p confers cisplatin resistance in NSCLC through activating autophagy. Int J Nanomedicine. 2019;14:8121–8132. doi:10.2147/IJN.S22138331632022
   PubMed Web of Science ®Google Scholar
• Wang C, Wang S, Ma F, Zhang W. miRNA328 overexpression confers cisplatin resistance in nonsmall cell lung cancer via targeting of PTEN. Mol Med Rep. 2018;18(5):4563–4570. doi:10.3892/mmr.2018.947830221716
   PubMed Web of Science ®Google Scholar
• Chen E, Li Q, Wang H, et al. MiR-32 promotes tumorigenesis of colorectal cancer by targeting BMP5. Biomed Pharmacother. 2018;106:1046–1051. doi:10.1016/j.biopha.2018.07.05030119170
   PubMed Web of Science ®Google Scholar
• Zhao L, Han T, Li Y, et al. The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB J. 2017;31(3):893–903. doi:10.1096/fj.201600994R27871067
   PubMed Web of Science ®Google Scholar
• Xia H, Long J, Zhang R, Yang X, Ma Z. MiR-32 contributed to cell proliferation of human breast cancer cells by suppressing of PHLPP2 expression. Biomed Pharmacother. 2015;75:105–110. doi:10.1016/j.biopha.2015.07.03726276160
   PubMed Web of Science ®Google Scholar
• Bai Y, Wang YL, Yao WJ, et al. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 2015;8(1):824–829.25755781
   PubMed Web of Science ®Google Scholar
• Li L, Wu D. miR-32 inhibits proliferation, epithelial-mesenchymal transition, and metastasis by targeting TWIST1 in non-small-cell lung cancer cells. Onco Targets Ther. 2016;9:1489–1498. doi:10.2147/OTT.S9993127042117
   PubMed Web of Science ®Google Scholar
• Shi Y, Qiu M, Wu Y, Hai L. MiR-548-3p functions as an anti-oncogenic regulator in breast cancer. Biomed Pharmacother. 2015;75:111–116. doi:10.1016/j.biopha.2015.07.02726297544
   PubMed Web of Science ®Google Scholar
• Zhu S, He C, Deng S, et al. MiR-548an, transcriptionally downregulated by HIF1alpha/HDAC1, suppresses tumorigenesis of pancreatic cancer by targeting vimentin expression. Mol Cancer Ther. 2016;15(9):2209–2219. doi:10.1158/1535-7163.MCT-15-087727353169
   PubMed Web of Science ®Google Scholar
• Labbe E, Lock L, Letamendia A, et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res. 2007;67(1):75–84. doi:10.1158/0008-5472.CAN-06-255917210685
   PubMed Web of Science ®Google Scholar
• He L, Luo L, Zhu H, et al. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer. Mol Oncol. 2017;11(6):640–654. doi:10.1002/1878-0261.1205828371273
   PubMed Web of Science ®Google Scholar
• Teng JP, Yang ZY, Zhu YM, Ni D, Zhu ZJ, Li XQ. Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo. Eur Rev Med Pharmacol Sci. 2018;22(12):3819–3825. doi:10.26355/eurrev_201806_1526629949158
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.38421892204
   PubMed Web of Science ®Google Scholar
• Xu S, Li J, Chen L, et al. Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy. Medicine (Baltimore). 2019;98(42):e17335. doi:10.1097/MD.000000000001733531626089
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu X, Li Z, Xiang J, Jiang J, Chen Z. microRNA expression profiling in multidrug resistance of the 5Fuinduced SGC7901 human gastric cancer cell line. Mol Med Rep. 2013;7(5):1506–1510. doi:10.3892/mmr.2013.138423525256
   PubMed Web of Science ®Google Scholar
• Jin D, Guo J, Wu Y, et al. Retraction of “UBE2C, directly targeted by miR-548e-5p, increases the cellular growth and invasive abilities of cancer cells interacting with the EMT marker protein zinc finger E-box binding homeobox 1/2 in NSCLC. Theranostics. 2020;10(21):9619. doi:10.7150/thno.5025432863949
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu X, Hou X, et al. miR-548b-3p functions as a tumor suppressor in lung cancer. Lasers Med Sci. 2020;35(4):833–839. doi:10.1007/s10103-019-02865-731485783
   PubMed Web of Science ®Google Scholar
• Sun X, Song S, Liang X, et al. ROBO1 polymorphisms, callosal connectivity, and reading skills. Hum Brain Mapp. 2017;38(5):2616–2626. doi:10.1002/hbm.2354628240421
   PubMed Web of Science ®Google Scholar
• Li XX, Jin L, Sun ZF, Gu F, Li WL, Ma YJ. [Robo1 expression in non-small cell lung cancer and its brain metastasis]. Zhonghua Zhong Liu Za Zhi. 2013;35(3):198–201. Chinese. doi:10.3760/cma.j.issn.0253-3766.2013.03.00823880000
   PubMedGoogle Scholar
• Chen P, Zhao Y, Li Y. [MiR-218 inhibits migration and invasion of lung cancer cell by regulating robo1 expression]. Zhongguo Fei Ai Za Zhi. 2017;20(7):452–458. Chinese. doi:10.3779/j.issn.1009-3419.2017.07.0328738960
   PubMedGoogle Scholar
• Fujiwara K, Koyama K, Suga K, et al. 90Y-labeled anti-ROBO1 monoclonal antibody exhibits antitumor activity against small cell lung cancer xenografts. PLoS One. 2015;10(5):e0125468. doi:10.1371/journal.pone.012546826017283
   PubMed Web of Science ®Google Scholar
• Eng L, Ibrahim-zada I, Jarjanazi H, et al. Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Med Genomics. 2011;4:18. doi:10.1186/1755-8794-4-1821314952
   PubMed Web of Science ®Google Scholar
• Siebzehnrubl FA, Silver DJ, Tugertimur B, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med. 2013;5(8):1196–1212. doi:10.1002/emmm.20130282723818228
   PubMed Web of Science ®Google Scholar
• Zhang QQ, Zhou DL, Lei Y, et al. Slit2/Robo1 signaling promotes intestinal tumorigenesis through Src-mediated activation of the Wnt/beta-catenin pathway. Oncotarget. 2015;6(5):3123–3135. doi:10.18632/oncotarget.306025605242
   PubMedGoogle Scholar
• Garg M, Maurya N. WNT/beta-catenin signaling in urothelial carcinoma of bladder. World J Nephrol. 2019;8(5):83–94. doi:10.5527/wjn.v8.i5.8331624709
   PubMedGoogle Scholar
• Ram Makena M, Gatla H, Verlekar D, Sukhavasi S, Pandey M, Pramanik K. Wnt/beta-catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance. Int J Mol Sci. 2019;20:17. doi:10.3390/ijms20174242
   Web of Science ®Google Scholar
• Yeh Y, Guo Q, Connelly Z, et al. Wnt/Beta-catenin signaling and prostate cancer therapy resistance. Adv Exp Med Biol. 2019;1210:351–378.31900917
   PubMed Web of Science ®Google Scholar
• Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50–60. doi:10.1016/j.ctrv.2017.11.00229169144
   PubMed Web of Science ®Google Scholar